The Brown University Child and Adolescent Psychopharmacology Update This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

FDA on ‘abuse‐deterrent’ opioids
Douglas C. Throckmorton, M.D., deputy center director for regulatory programs in the Food and Drug Administration's Center for Drug Evaluation and Research, shared some key facts on “abuse‐deterrent” opioids. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - November 23, 2016 Category: Psychiatry Tags: From the FDA Source Type: research

Shire announces new update to BED medication labeling
Vyvanse (lisdexamfetamine dimesylate) labeling has been updated to include information regarding the approval of a supplemental New Drug Application by the Food and Drug Administration (FDA). The labeling will now include maintenance of efficacy data from the first‐ever longer‐term pharmacologic study (38 weeks) in adults with moderate‐to‐severe binge eating disorder (BED), Shire officials announced. The data were presented at a few medical conferences including the Eating Disorders Association of Canada in September, and during the American College of Neuropsychopharmacology Annual Meeting a year ago. The updated ...
Source: The Brown University Child and Adolescent Psychopharmacology Update - November 23, 2016 Category: Psychiatry Tags: News Source Type: research

Depression study of teens and young adults calls for urgency
New research examining the depression prevalence and treatment trends among adolescents and young adults calls for a sense of urgency regarding treatment for youth with depression. A study published in Pediatrics in November, “National Trends in the Prevalence and Treatment of Depression in Adolescents and Young Adults,” reports a significant climb in the prevalence of major depression in youth in recent years, particularly strongest in teenage girls. In a commentary to the article, Anne Glowinski, M.D., MPE, director of child and adolescent psychiatry education and training and associate director of the William Greenl...
Source: The Brown University Child and Adolescent Psychopharmacology Update - November 23, 2016 Category: Psychiatry Tags: News Source Type: research

CBT still considered best treatment for children exposed to trauma
An update on the evidence based on psychosocial treatments for children and adolescents exposed to trauma found that cognitive behavioral therapy (CBT) is still the best treatment modality for them. The update comes 7 years after the initial report. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - November 23, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

Cause for concern on concurrent marijuana, alcohol use
As shifting marijuana policy continues to diminish the perceived risk of marijuana use among young smokers, there becomes reason for significant concern over concurrent use of marijuana and alcohol in this population. Numerous published studies in the past couple of years have shown worrisome effects from combined use of the drugs, with evidence that each can function to exacerbate the effects of the other. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - November 23, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

Study compares comorbid ASD and BD in youth with BD alone
Researchers looked at differences between youth with high‐functioning autism spectrum disorder (ASD) and bipolar disorder (BD), and youth with BD alone, to characterize mood and psychosocial functioning over time. They found that trajectories are similar over time, but that youth with both disorders have additional symptoms that peak in early teenage years. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - November 23, 2016 Category: Psychiatry Tags: Autism Spectrum Disorders Source Type: research

Metformin found effective for reversing weight gain in children with ASD treated with antipsychotics
Atypical antipsychotic medications in children with autism spectrum disorder (ASD) are indicated for related irritability and agitation. These medications are associated with weight gain and metabolic complications, so researchers wanted to evaluate the efficacy of metformin. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - October 27, 2016 Category: Psychiatry Tags: Autism Source Type: research

FDA regulates all tobacco products, protecting minors
This summer, the federal Food and Drug Administration finalized its rule prohibiting retailers from selling e‐cigarettes, hookah tobacco, or cigars to people under 18. For years, it has been illegal under federal law to sell cigarettes and smokeless tobacco to minors. Now the FDA is helping to protect the public, and especially children, from the dangers of all tobacco products. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - October 26, 2016 Category: Psychiatry Tags: From the FDA Source Type: research

Reporting requirements issued for buprenorphine prescribers with more than 100 patients
(Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - October 26, 2016 Category: Psychiatry Tags: Research Roundup Source Type: research

Buprenorphine: 56 ‐day taper superior to 28 days in youth and young adults
This study looked at two different taper lengths, and not at maintenance. The findings were clear: the longer taper (56 days) had much better results than the shorter one (28 days). (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - October 26, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

New diagnosis proposed for disorder associated with prenatal alcohol exposure
While fetal alcohol syndrome (FAS) is a well‐established diagnosis, children and adolescents who do not have the syndrome but have been affected by prenatal exposure to alcohol may have brain damage resulting in impairments of neurocognition, self‐regulation, and adaptive functioning, according to experts from the American Academy of Pediatrics (AAP). In a special article, guidelines for the identification, diagnosis, and referral of these children are described, with emphasis on behaviors that can be identified in pediatric medical homes. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - October 26, 2016 Category: Psychiatry Tags: What's New in Research Source Type: research

Mental health education in N.Y. schools required as of 2018
New York state will require all public school districts to teach mental health to middle and high school students starting in 2018. As part of the preparation process, mental health advocates are working with the school districts to set the curriculum. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - October 26, 2016 Category: Psychiatry Tags: Prevention Source Type: research

Aripiprazole associated with adverse effects in pediatric population
Citing the scarcity of evidence regarding the use of aripiprazole in children and adolescents, researchers undertook a study of adverse drug reaction (ADR) reports in children and adolescents. Although aripiprazole is considered safe and well‐tolerated in children, there have been severe adverse events. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - September 27, 2016 Category: Psychiatry Tags: Adverse Effects Source Type: research

FDA requires black box warnings for combining benzodiazepines and opioids
The Food and Drug Administration announced late last month that it would require classwide changes to labeling of benzodiazepines and certain opioids, including cough products containing opioids. The move is in response to the opioid epidemic. (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - September 25, 2016 Category: Psychiatry Tags: From the FDA Source Type: research

Research Roundup
NIH teen brain study begins recruitment Atomoxetine improves reading skills in children with dyslexia Reduced IQ, polygenic risk scores for psychosis linked (Source: The Brown University Child and Adolescent Psychopharmacology Update)
Source: The Brown University Child and Adolescent Psychopharmacology Update - September 25, 2016 Category: Psychiatry Tags: Research Roundup Source Type: research